



Fax completed form to: (855) 840-1678  
 If this is an URGENT request, please call (800) 882-4462  
 (800.88.CIGNA)

# Rybrevant (*amivantamab-vmjw*)/ Rybrevant Faspro (*amivantamab and hyaluronidase-lpuj*)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:	* Date of Birth:	
Office Fax:			* Patient Street Address:		
Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		
<b>Urgency:</b> <input type="checkbox"/> Standard <input type="checkbox"/> Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)					
<b>Medication Requested:</b> <input type="checkbox"/> Rybrevant 350mg/7mL solution for injection <input type="checkbox"/> Rybrevant Faspro 1,600 mg and 20,000 units/10 mL vial <input type="checkbox"/> Rybrevant Faspro 2,240 mg and 28,000 units/14 mL vial <input type="checkbox"/> Rybrevant Faspro 2,400 mg and 30,000 units/15 mL vial <input type="checkbox"/> Rybrevant Faspro 3,520 mg and 44,000 units/22 mL vial  Dose: _____ Frequency of therapy: _____ Duration of therapy: _____  ICD10: _____					
<b>Where will this medication be obtained?</b> <input type="checkbox"/> Accredro Specialty Pharmacy** <input type="checkbox"/> Retail pharmacy <input type="checkbox"/> Prescriber's office stock (billing on a medical claim form) <input type="checkbox"/> Home Health / Home Infusion vendor <input type="checkbox"/> Other (please specify): _____                      **Cigna's nationally preferred specialty pharmacy					
<i>**Medication orders can be placed with Accredro via E-prescribe - Accredro (1620 Century Center Pkwy, Memphis, TN 38134-8822   NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557</i>					
<b>Facility and/or doctor dispensing and administering medication:</b> Facility Name: _____ State: _____ Tax ID#: _____ Address (City, State, Zip Code): _____  <p style="text-align: center;"><b>NOTE:</b> Per some Cigna plans, infusion of medication MUST occur in the lowest cost, medically appropriate setting</p> Is this infusion occurring in a facility affiliated with hospital outpatient setting? <input type="checkbox"/> Yes <input type="checkbox"/> No  If yes- Is this patient a candidate for re-direction to an alternate setting (such as AIS, MDO, home) with assistance of a Specialty Care Option Case Manager? <input type="checkbox"/> Yes <input type="checkbox"/> No (provide medical necessity rationale): _____					
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? <input type="checkbox"/> Yes <input type="checkbox"/> No					
<b>Diagnosis related to use:</b> <input type="checkbox"/> non-small cell lung cancer (NSCLC) <input type="checkbox"/> other					
<b>Clinical Information</b>  (if NSCLC) Does the patient have locally advanced or metastatic disease? <input type="checkbox"/> Yes <input type="checkbox"/> No					

(if NSCLC) Does the patient have epidermal growth factor receptor (EGFR) exon 20 insertion mutations?  Yes  No

(if NSCLC, if exon 20) Will this medication be used as first line treatment in combination with carboplatin and pemetrexed?  Yes  No

(if no) Will the medication be used as a single agent treatment?  Yes  No

(if yes) Has the patient's disease progressed on or after platinum-based chemotherapy?  Yes  No

(if NSCLC, if not exon 20) Does the patient have epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations?  Yes  No

(if exon 19/21) Is/Will this medication be(ing) used in combination with lazertinib?  Yes  No

(if exon 19/21) Is this the first treatment the patient has received for this diagnosis?  Yes  No

(if no) Is/Will this medication be(ing) used as continuation of therapy with disease progression on amivantamab-vmjw with lazertinib?  Yes  No

(if continuation) Which of the following best describes the patient's disease?

- asymptomatic disease
- symptomatic brain lesions
- symptomatic systemic limited progression
- none of the above

**Additional pertinent information:**

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

**Prescriber Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**Save Time! Submit Online at: [www.covermy meds.com/main/prior-authorization-forms/cigna/](http://www.covermy meds.com/main/prior-authorization-forms/cigna/) or via SureScripts in your EHR.**

*Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at [cigna.com](http://cigna.com).*

v040126

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005